MCID: ETN001
MIFTS: 64

Eating Disorder

Categories: Mental diseases, Metabolic diseases, Neuronal diseases

Aliases & Classifications for Eating Disorder

MalaCards integrated aliases for Eating Disorder:

Name: Eating Disorder 12 15
Eating Disorders 37 55 43 73
Feeding and Eating Disorders 44

Classifications:



External Ids:

Disease Ontology 12 DOID:8670
ICD10 33 F50 F50.9
ICD9CM 35 307.50
MeSH 44 D001068
NCIt 50 C89332
SNOMED-CT 68 72366004
KEGG 37 H01703
UMLS 73 C0013473

Summaries for Eating Disorder

MedlinePlus : 43 Eating disorders are serious behavior problems. They can include severe overeating or not consuming enough food to stay healthy. They also involve extreme concern about your shape or weight. Types of eating disorders include Anorexia nervosa, in which you become too thin, but you don't eat enough because you think you are fat Bulimia nervosa, which involves periods of overeating followed by purging, sometimes through self-induced vomiting or using laxatives Binge-eating, which is out-of-control eating Women are more likely than men to have eating disorders. They usually start in the teenage years and often occur along with depression, anxiety disorders, and substance abuse. Eating disorders can lead to heart and kidney problems and even death. Getting help early is important. Treatment involves monitoring, talk therapy, nutritional counseling, and sometimes medicines. NIH: National Institute of Mental Health

MalaCards based summary : Eating Disorder, also known as eating disorders, is related to bulimia nervosa and borderline personality disorder, and has symptoms including decrease in appetite, adipsia and symptoms concerning nutrition, metabolism, and development. An important gene associated with Eating Disorder is GHRL (Ghrelin And Obestatin Prepropeptide), and among its related pathways/superpathways are Adipocytokine signaling pathway and cAMP signaling pathway. The drugs Dopamine and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and bone, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A specific developmental disorder that is characterized by abnormal eating habits that may involve either insufficient or excessive food intake to the detriment of an individual's physical and emotional health.

Wikipedia : 76 An eating disorder is a mental disorder defined by abnormal eating habits that negatively affect a... more...

Related Diseases for Eating Disorder

Diseases related to Eating Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 233)
# Related Disease Score Top Affiliating Genes
1 bulimia nervosa 32.6 BDNF CCK COMT GHRL LEP MC4R
2 borderline personality disorder 31.8 BDNF COMT HTR2C SLC6A4
3 gastroparesis 31.3 CCK DRD2 GHRL
4 anorexia nervosa 30.9 ADIPOQ BDNF CCK COMT CRH GHRL
5 alexithymia 30.9 COMT DRD2 SLC6A4
6 depression 30.7 BDNF CRH HTR2C SLC6A4
7 personality disorder 30.4 BDNF COMT DRD2 HTR2C SLC6A3 SLC6A4
8 amenorrhea 30.3 CRH LEP POMC
9 pathological gambling 30.2 DRD2 SLC6A3 SLC6A4
10 alcohol abuse 30.2 BDNF CNR1 DRD2 SLC6A4
11 fibromyalgia 30.1 COMT CRH NPY SLC6A4
12 celiac disease 1 30.1 CCK GHRL PYY
13 dyspepsia 30.0 CCK GHRL SLC6A4
14 attention deficit-hyperactivity disorder 30.0 BDNF COMT DRD2 HTR2C NPY SLC6A3
15 social phobia 30.0 CCK DRD2 SLC6A4
16 cocaine abuse 29.9 DRD2 SLC6A3 SLC6A4
17 anxiety 29.9 BDNF CNR1 COMT CRH CRHR2 HTR2C
18 obsessive-compulsive disorder 29.9 BDNF COMT CRH DRD2 HTR2C SLC6A3
19 autism 29.9 BDNF COMT DRD2 SLC6A3 SLC6A4
20 brain injury 29.8 BDNF COMT DRD2
21 substance abuse 29.7 BDNF COMT DRD2 NPY SLC6A3 SLC6A4
22 narcolepsy 29.7 COMT DRD2 GHRL LEP SLC6A3
23 generalized anxiety disorder 29.7 BDNF COMT DRD2 SLC6A4
24 bipolar disorder 29.7 BDNF COMT CRH DRD2 HTR2C SLC6A3
25 substance dependence 29.7 BDNF CNR1 DRD2 POMC SLC6A3 SLC6A4
26 tobacco addiction 29.6 COMT DRD2 SLC6A3 SLC6A4
27 withdrawal disorder 29.5 CNR1 CRH POMC
28 restless legs syndrome 29.5 DRD2 POMC SLC6A3
29 morbid obesity 29.5 ADIPOQ CCK GHRL LEP LEPR MC4R
30 sleep apnea 29.4 ADIPOQ GHRL LEP LEPR
31 fatty liver disease 29.3 ADIPOQ LEP LEPR
32 irritable bowel syndrome 29.3 CCK CRH CRHR2 PYY SLC6A4
33 post-traumatic stress disorder 29.2 BDNF CNR1 COMT CRH DRD2 SLC6A4
34 mood disorder 29.2 BDNF COMT CRH DRD2 HTR2C NPY
35 schizophrenia 29.1 BDNF CCK CNR1 COMT DRD2 HTR2C
36 diabetes mellitus, noninsulin-dependent 29.1 ADIPOQ CNR1 GHRL LEP LEPR MC4R
37 disease of mental health 28.9 BDNF CCK CNR1 COMT CRH DRD2
38 major depressive disorder 28.8 BDNF COMT CRH DRD2 HTR2C NPY
39 panic disorder 28.7 BDNF CCK COMT CRH CRHR2 HTR2C
40 body mass index quantitative trait locus 11 28.3 ADIPOQ CCK CNR1 CRH DRD2 GHRL
41 rumination disorder 11.6
42 pica disease 11.1
43 autism spectrum disorder 11.1
44 extrapontine myelinolysis 11.1
45 wernicke-korsakoff syndrome 10.9
46 osteoporosis, juvenile 10.7
47 telogen effluvium 10.7
48 central pontine myelinolysis 10.7
49 brittle diabetes 10.7
50 mbd25-related intellectual disability 10.7

Comorbidity relations with Eating Disorder via Phenotypic Disease Network (PDN):


Major Depressive Disorder

Graphical network of the top 20 diseases related to Eating Disorder:



Diseases related to Eating Disorder

Symptoms & Phenotypes for Eating Disorder

UMLS symptoms related to Eating Disorder:


decrease in appetite, adipsia, symptoms concerning nutrition, metabolism, and development

MGI Mouse Phenotypes related to Eating Disorder:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.54 ADIPOQ BDNF CCK CNR1 COMT CRH
2 homeostasis/metabolism MP:0005376 10.49 ADIPOQ BDNF CCK CNR1 COMT CRH
3 adipose tissue MP:0005375 10.4 ADIPOQ CNR1 CRH CRHR2 DRD2 GHRL
4 growth/size/body region MP:0005378 10.39 ADIPOQ BDNF CNR1 CRH DRD2 HTR2C
5 endocrine/exocrine gland MP:0005379 10.37 ADIPOQ BDNF CCK COMT CRH CRHR2
6 nervous system MP:0003631 10.34 ADIPOQ BDNF CCK CNR1 COMT CRH
7 immune system MP:0005387 10.26 ADIPOQ COMT CRH CRHR2 DRD2 HTR2C
8 integument MP:0010771 10.25 ADIPOQ BDNF CNR1 CRH DRD2 HTR2C
9 cardiovascular system MP:0005385 10.23 ADIPOQ COMT CRHR2 DRD2 LEP LEPR
10 digestive/alimentary MP:0005381 10.11 BDNF CNR1 DRD2 GHRL LEP LEPR
11 normal MP:0002873 10.11 BDNF CNR1 CRH DRD2 GHRL LEPR
12 liver/biliary system MP:0005370 10.1 ADIPOQ CRH DRD2 LEP LEPR MC4R
13 muscle MP:0005369 10.02 ADIPOQ DRD2 HTR2C LEP LEPR SLC6A3
14 no phenotypic analysis MP:0003012 10.01 BDNF CCK CNR1 CRH DRD2 LEPR
15 renal/urinary system MP:0005367 9.97 ADIPOQ CCK COMT CRH DRD2 LEP
16 neoplasm MP:0002006 9.93 ADIPOQ DRD2 LEP LEPR MC4R POMC
17 reproductive system MP:0005389 9.86 BDNF CNR1 COMT DRD2 LEP LEPR
18 respiratory system MP:0005388 9.76 ADIPOQ BDNF COMT CRH DRD2 LEP
19 skeleton MP:0005390 9.65 ADIPOQ CNR1 CRH DRD2 LEP LEPR
20 taste/olfaction MP:0005394 8.92 BDNF CNR1 DRD2 SLC6A3

Drugs & Therapeutics for Eating Disorder

Drugs for Eating Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 295)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
2
Aripiprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 129722-12-9 60795
3
Fluoxetine Approved, Vet_approved Phase 4,Not Applicable 54910-89-3 3386
4
Topiramate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 97240-79-4 5284627
5
leucovorin Approved Phase 4 58-05-9 6006 143
6
Dextroamphetamine Approved, Illicit Phase 4,Phase 2 51-64-9 5826
7
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 2 300-62-9 5826 3007
8
Memantine Approved, Investigational Phase 4,Not Applicable 19982-08-2 4054
9
Norepinephrine Approved Phase 4,Phase 2,Not Applicable 51-41-2 439260
10
Ethanol Approved Phase 4,Phase 2,Phase 3,Not Applicable 64-17-5 702
11
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 16590-41-3 5360515
12
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 132539-06-1 4585
13
Risperidone Approved, Investigational Phase 4,Not Applicable 106266-06-2 5073
14
Liraglutide Approved Phase 4,Phase 3 204656-20-2 44147092
15
Baclofen Approved Phase 4,Not Applicable 1134-47-0 2284
16
Donepezil Approved Phase 4,Phase 3,Phase 2 120014-06-4 3152
17
Orlistat Approved, Investigational Phase 4,Not Applicable 96829-58-2 3034010
18
Galantamine Approved Phase 4,Phase 3 357-70-0 9651
19
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
20
Phentermine Approved, Illicit Phase 4,Phase 2,Phase 1 122-09-8 4771
21
Zinc Approved, Investigational Phase 4,Phase 1,Phase 2 7440-66-6
22
Histamine Approved, Investigational Phase 4,Not Applicable 51-45-6, 75614-87-8 774
23
Cyproheptadine Approved Phase 4 129-03-3 2913
24
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
26
Choline Approved, Nutraceutical Phase 4 62-49-7 305
27 Raclopride Investigational Phase 4 84225-95-6
28 Vitamins Phase 4,Phase 3,Not Applicable
29 Vitamin B9 Phase 4
30 Folate Phase 4
31 Micronutrients Phase 4,Phase 1,Phase 2
32 Trace Elements Phase 4,Phase 1,Phase 2
33 Vitamin B Complex Phase 4
34 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
36 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
37 Dopamine Agents Phase 4,Phase 3,Phase 2,Not Applicable
38 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
39 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
40 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
42 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Antiparkinson Agents Phase 4,Phase 3,Not Applicable
46 Antidepressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
47 Narcotic Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
48 Narcotics Phase 4,Phase 2,Phase 3,Not Applicable
49 Serotonin Agents Phase 4,Phase 3,Phase 2,Not Applicable
50 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 695)
# Name Status NCT ID Phase Drugs
1 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
2 Folic Acid Supplementation in Eating Disorder Completed NCT01493674 Phase 4
3 Monoamine Contributions to Neurocircuitry in Eating Disorders Completed NCT02020408 Phase 4 [11C]raclopride;[11C]DASB;amphetamine
4 An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder Completed NCT00330655 Phase 4 memantine
5 Effectiveness of Binge Eating Disorder Treatments Completed NCT00060762 Phase 4
6 Atomoxetine in the Treatment of Binge Eating Disorder Completed NCT00327834 Phase 4 atomoxetine
7 Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression Completed NCT00607789 Phase 4 Duloxetine;Placebo
8 Naltrexone Treatment for Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
9 Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa Completed NCT00685334 Phase 4 Olanzapine;Aripiprazole
10 Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa Completed NCT00288574 Phase 4 Fluoxetine;Placebo
11 The Effects of Body Contouring: Abdominoplasty and Liposuction Completed NCT02151799 Phase 4
12 A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa Completed NCT00140426 Phase 4 Risperidone;Placebo
13 Effect of Early Oral Triple Viable Bifidobacterium Intestinal Flora in Preterm Completed NCT02060084 Phase 4 a control group;a probiotic-supplemented group
14 Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and Obese Completed NCT01739049 Phase 4 Liraglutide
15 Olanzapine in the Treatment of Anorexia Nervosa Completed NCT00592930 Phase 4 olanzapine;placebo
16 Baclofen for Rumination Completed NCT03113396 Phase 4 Baclofen;Placebo oral capsule
17 Treatment of Binge Eating in Obese Patients in Primary Care Completed NCT00537810 Phase 4 Sibutramine;Placebo
18 Impact of Behavioral Feeding Intervention on Parent-Child Attachment in Young Children Completed NCT02187952 Phase 4
19 The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease Completed NCT00381381 Phase 4 Donepezil
20 Study of Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons Completed NCT00516919 Phase 4 Xenical + behavioral intervention
21 The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life Completed NCT00814658 Phase 4 Galantamine;Nimodipine;Placebo
22 Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese Adults Completed NCT02706067 Phase 4 Orlistat
23 Near Infrared Spectroscopy (NIRS) and Superior Mesenteric Artery (SMA) Doppler Patterns as Predictor of Feeding Tolerance in Very Low Birth Weight (VLBW) IntraUterine Growth Restricted (IUGR) and NON IUGR Infants Completed NCT01341236 Phase 4
24 Evaluation of the Efficacy of Serotoninergic Antidepressants in Bulimia Nervosa, According to Brain Serotonin Profile Determined by Positron Emission Tomography With [18F] MPPF. Recruiting NCT02359513 Phase 4 Antidepressants;Positron Emission Tomography (PET)
25 Lifestyle Modification and Liraglutide Active, not recruiting NCT02911818 Phase 4 Liraglutide 3.0mg;Placebo Oral Tablet;Phentermine 15 MG
26 Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment Not yet recruiting NCT03779048 Phase 4 Placebo;Liraglutide 3.0 mg
27 iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children 9 Months to 5 Years 6 Months of Age Not yet recruiting NCT03815019 Phase 4 Megestrol Acetate
28 Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders Not yet recruiting NCT02568007 Phase 4 Cyproheptadine
29 Effect of Zinc Supplementation on Appetite and Growth in Primary Malnourished Children Not yet recruiting NCT03098810 Phase 4 Zinc sulphate
30 Does Hydroxyzine Decrease Anxiety in Underweight Patients Diagnosed With an Eating Disorder Withdrawn NCT01372670 Phase 4 Hydroxyzine;hydroxyzine HCL
31 Topiramate Augmentation in Bulimia Nervosa Partial Responders Withdrawn NCT00988481 Phase 4 Topiramate
32 Clinical Trial on Binge Eating Disorder, Treatment With Naloxone Spray Unknown status NCT01567670 Phase 2, Phase 3 Naloxone;naloxone placebo
33 Improving Patient Outcome in Group Therapy for Eating Disorders Unknown status NCT01693237 Phase 2, Phase 3
34 The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa Unknown status NCT00220662 Phase 3
35 A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial) Unknown status NCT01801397 Phase 3 osteoanabolic therapy
36 ARIpiprazole in Anorexia NErvosa Unknown status NCT01082848 Phase 3 aripiprazole;placebo
37 A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder Completed NCT03107026 Phase 3 dasotraline 4mg;dasotraline 6mg;Placebo
38 Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity Completed NCT00277641 Phase 3 Lamotrigine;placebo
39 Deficits in Emotion Regulation Skills as a Maintaining Factor in Binge Eating Disorder Completed NCT03717493 Phase 2, Phase 3
40 Dasotraline Binge Eating Disorder Study Completed NCT02564588 Phase 2, Phase 3 Dasotraline;Placebo
41 Open Label Extension in Adults With Binge Eating Disorder (BED) Completed NCT01657019 Phase 3 Lisdexamfetamine dimesylate
42 SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718483 Phase 3 SPD489 (Lisdexamfetamine dimesylate);Placebo
43 Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder Completed NCT01090713 Phase 3 lisdexamfetamine;Placebo control
44 SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718509 Phase 3 SPD489 (Lisdexamfetamine dimesylate);Placebo
45 Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity Completed NCT00221442 Phase 3 Zonegran;sugar pill
46 A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity Completed NCT00210808 Phase 2, Phase 3 topiramate
47 Meditation-Based Treatment for Binge Eating Disorder Completed NCT00032760 Phase 2, Phase 3
48 An Efficacy and Tolerability Study for Topiramate in Obese Patients With Binge Eating Disorder. Completed NCT00307619 Phase 3 topiramate
49 Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT02009163 Phase 3 Lisdexamfetamine dimesylate
50 A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder Completed NCT00402584 Phase 3 sibutramine

Search NIH Clinical Center for Eating Disorder

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: feeding and eating disorders

Genetic Tests for Eating Disorder

Anatomical Context for Eating Disorder

MalaCards organs/tissues related to Eating Disorder:

41
Brain, Testes, Bone, Kidney, Heart, Liver, Breast

Publications for Eating Disorder

Articles related to Eating Disorder:

(show top 50) (show all 2848)
# Title Authors Year
1
Meta-analysis of the effects of third-wave behavioural interventions on disordered eating and body image concerns: implications for eating disorder prevention. ( 30307377 )
2019
2
Is it Important to Talk About Technologies with Eating Disorder Clients? The Health-Care Professional Perspective. ( 29028370 )
2019
3
Food specific inhibitory control under negative mood in binge-eating disorder: Evidence from a multimethod approach. ( 29341203 )
2018
4
Implicit and explicit changes in body satisfaction evoked by body size illusions: Implications for eating disorder vulnerability in women. ( 29928005 )
2018
5
Beyond the tip of the iceberg: Adolescent weight development of women and men with features of binge eating disorder. ( 29933124 )
2018
6
Binge eating disorder and morbid obesity are associated with lowered mu-opioid receptor availability in the brain. ( 29655552 )
2018
7
Do eating disorder voice characteristics predict treatment outcomes in anorexia nervosa? A pilot study. ( 29882721 )
2018
8
An examination of eating disorder education and experience in a 1-month adolescent medicine rotation: what is sufficient to foster adequate self-efficacy? ( 29953405 )
2018
9
Stress-induced eating in women with binge-eating disorder and obesity. ( 27836626 )
2018
10
The Contribution of Social Media to Body Dissatisfaction, Eating Disorder Symptoms, and Anabolic Steroid Use Among Sexual Minority Men. ( 29363993 )
2018
11
Psychological, pharmacological, and combined treatments for binge eating disorder: a systematic review and meta-analysis. ( 29942715 )
2018
12
Eating Disorder Symptomatology and Identity Formation in Adolescence: A Cross-Lagged Longitudinal Approach. ( 29915548 )
2018
13
Improving access to eating disorder services. ( 29378681 )
2018
14
Media Smart-Targeted: Diagnostic outcomes from a two-country pragmatic online eating disorder risk reduction trial for young adults. ( 29377203 )
2018
15
The relationship between trauma and weight status among adolescents in eating disorder treatment. ( 29969660 )
2018
16
Cyber Victimization Is Associated With Eating Disorder Psychopathology in Adolescents. ( 29962992 )
2018
17
Would glucagon-like peptide-1 receptor agonists have efficacy in binge eating disorder and bulimia nervosa? A review of the current literature. ( 29407005 )
2018
18
Subjective and Objective: Alexithymia and Social Cognition in Eating Disorders. ( 29916406 )
2018
19
A content analysis of an online pro-eating disorder community on Reddit. ( 29414146 )
2018
20
Network analysis: An innovative framework for understanding eating disorder psychopathology. ( 29451959 )
2018
21
A Screening Tool for Detecting Eating Disorder Risk and Diagnostic Symptoms among College-Age Women. ( 29979922 )
2018
22
Binge eating disorder and depressive symptoms among females of child-bearing age: the Korea Nurses' Health Study. ( 29343226 )
2018
23
Perfectionism is associated with higher eating disorder symptoms and lower remission in children and adolescents diagnosed with eating disorders. ( 29803120 )
2018
24
Ghrelin concentration as an indicator of eating-disorder risk in obese women. ( 29395813 )
2018
25
Meta-analysis of the effects of cognitive-behavioral therapy on the core eating disorder maintaining mechanisms: implications for mechanisms of therapeutic change. ( 29378481 )
2018
26
The relationship between body mass index, binge eating disorder and suicidality. ( 29907143 )
2018
27
Acute Massive Gastric Dilatation in a Patient with an Eating Disorder. ( 29491312 )
2018
28
Fasting and postprandial soluble epoxide hydrolase-associated eicosanoids of remitted patients with eating disorder. ( 29876402 )
2018
29
How Does Food Taste in Anorexia and Bulimia Nervosa? A Protocol for a Quasi-Experimental, Cross-Sectional Design to Investigate Taste Aversion or Increased Hedonic Valence of Food in Eating Disorders. ( 29593595 )
2018
30
Patient Experiences Using a Self-Monitoring App in Eating Disorder Treatment: Qualitative Study. ( 29934285 )
2018
31
Childhood body mass index and development of eating disorder traits across adolescence. ( 29927002 )
2018
32
Patients with Binge Eating Disorder and Obesity have qualitatively different interpersonal characteristics: Results from an Interpersonal Circumplex study. ( 29960139 )
2018
33
Associations among eating disorder behaviors and eating disorder quality of life in adult women with anorexia nervosa. ( 29886272 )
2018
34
Feeling fat in eating disorders: Testing the unique relationships between feeling fat and measures of disordered eating in anorexia nervosa and bulimia nervosa. ( 29653375 )
2018
35
Eating disorder or oesophageal achalasia during adolescence: diagnostic difficulties. ( 29774515 )
2018
36
Variation in reproductive outcomes of women with histories of bulimia nervosa, anorexia nervosa, or eating disorder not otherwise specified relative to the general population and closest-aged sisters. ( 29331083 )
2018
37
The impact of self-imagery on aspects of the self-concept in individuals with high levels of eating disorder cognitions. ( 29859373 )
2018
38
Economic evaluation of cognitive behavioral therapy and Internet-based guided self-help for binge-eating disorder. ( 29345848 )
2018
39
Subjective incompetence as a predictor of treatment outcomes in eating disorder outpatients. ( 29870956 )
2018
40
Neuroimaging in bulimia nervosa and binge eating disorder: a systematic review. ( 29468065 )
2018
41
Validation of the Spanish Version of the Yale Food Addiction Scale 2.0 (YFAS 2.0) and Clinical Correlates in a Sample of Eating Disorder, Gambling Disorder, and Healthy Control Participants. ( 29887808 )
2018
42
Hypomagnesemia in a Patient With an Eating Disorder. ( 29389386 )
2018
43
Implementation of enhanced cognitive behaviour therapy (CBT-E) for adults with anorexia nervosa in an outpatient eating-disorder unit at a public hospital. ( 29854400 )
2018
44
Affective predictors of the severity and change in eating psychopathology in residential eating disorder treatment: The role of social anxiety. ( 29384466 )
2018
45
Effect of dopamine receptor D4 (DRD4) haplotypes on general psychopathology in patients with eating disorders. ( 29455021 )
2018
46
Body composition and physical fitness in women with bulimia nervosa or binge-eating disorder. ( 29473191 )
2018
47
Increased prevalence of eating disorders as a biopsychosocial implication of food allergy. ( 29944672 )
2018
48
Beyond the Binary: Differences in Eating Disorder Prevalence by Gender Identity in a Transgender Sample. ( 29359198 )
2018
49
A narrative review of binge eating disorder in adolescence: prevalence, impact, and psychological treatment strategies. ( 29379325 )
2018
50
Alexithymia explains increased empathic personal distress in individuals with and without eating disorders. ( 30428774 )
2018

Variations for Eating Disorder

Expression for Eating Disorder

Search GEO for disease gene expression data for Eating Disorder.

Pathways for Eating Disorder

Pathways related to Eating Disorder according to KEGG:

37
# Name Kegg Source Accession
1 Adipocytokine signaling pathway hsa04920
2 cAMP signaling pathway hsa04024

Pathways related to Eating Disorder according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.94 CCK CNR1 CRH CRHR2 DRD2 GHRL
2
Show member pathways
12.73 BDNF CNR1 CRH CRHR2 DRD2 HTR2C
3
Show member pathways
12.7 CCK CNR1 CRH CRHR2 DRD2 GHRL
4 12.39 CNR1 COMT NPY POMC
5
Show member pathways
12.1 BDNF DRD2 GHRL NPY
6
Show member pathways
12.04 CRHR2 GHRL LEP POMC
8 11.92 CRH CRHR2 MC4R POMC
9
Show member pathways
11.79 BDNF DRD2 SLC6A3
10 11.65 CRH CRHR2 POMC
11 11.19 ADIPOQ LEP LEPR NPY POMC
12
Show member pathways
11.06 LEP LEPR POMC
13
Show member pathways
10.96 COMT SLC6A3 SLC6A4
14 10.77 MC4R POMC
15 10.64 CCK CNR1
16 10.28 CRH CRHR2 POMC

GO Terms for Eating Disorder

Cellular components related to Eating Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.97 ADIPOQ BDNF CCK CRH GHRL LEP
2 extracellular region GO:0005576 9.96 ADIPOQ BDNF CCK CRH GHRL LEP
3 dendrite GO:0030425 9.63 BDNF CCK COMT CRHR2 DRD2 HTR2C
4 perikaryon GO:0043204 9.61 CCK CRH DRD2
5 integral component of postsynaptic membrane GO:0099055 9.54 DRD2 SLC6A3 SLC6A4
6 dopaminergic synapse GO:0098691 9.4 DRD2 SLC6A3
7 integral component of presynaptic membrane GO:0099056 9.26 CNR1 DRD2 SLC6A3 SLC6A4
8 axon GO:0030424 9.23 BDNF CCK CNR1 COMT CRHR2 DRD2

Biological processes related to Eating Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.94 ADIPOQ DRD2 LEP SLC6A4
2 neuropeptide signaling pathway GO:0007218 9.88 NPY POMC PYY
3 female pregnancy GO:0007565 9.87 COMT CRH LEP
4 locomotory behavior GO:0007626 9.87 DRD2 HTR2C SLC6A3
5 circadian rhythm GO:0007623 9.87 ADIPOQ LEP SLC6A4
6 response to drug GO:0042493 9.87 ADIPOQ COMT CRH DRD2 HTR2C SLC6A3
7 regulation of signaling receptor activity GO:0010469 9.86 ADIPOQ BDNF CCK GHRL LEP NPY
8 response to estrogen GO:0043627 9.84 COMT CRH GHRL
9 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.84 CNR1 HTR2C NPY
10 positive regulation of cold-induced thermogenesis GO:0120162 9.84 ADIPOQ GHRL LEP LEPR
11 regulation of blood pressure GO:0008217 9.83 LEP NPY POMC
12 glucose metabolic process GO:0006006 9.83 ADIPOQ GHRL LEP
13 response to nutrient levels GO:0031667 9.83 ADIPOQ GHRL LEP
14 response to nutrient GO:0007584 9.83 ADIPOQ CNR1 LEP SLC6A4
15 memory GO:0007613 9.81 BDNF CCK CNR1 SLC6A4
16 response to nicotine GO:0035094 9.77 CNR1 DRD2 SLC6A3
17 positive regulation of multicellular organism growth GO:0040018 9.77 DRD2 GHRL SLC6A3
18 glucose homeostasis GO:0042593 9.77 ADIPOQ CNR1 LEP LEPR POMC
19 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.76 CNR1 CRHR2 DRD2 MC4R
20 negative regulation of blood pressure GO:0045776 9.74 ADIPOQ CNR1 DRD2
21 response to pain GO:0048265 9.72 COMT CRH
22 response to iron ion GO:0010039 9.72 DRD2 SLC6A3
23 synaptic transmission, dopaminergic GO:0001963 9.72 CRH DRD2
24 dopamine metabolic process GO:0042417 9.71 COMT DRD2
25 negative regulation of gluconeogenesis GO:0045721 9.71 ADIPOQ LEPR
26 prepulse inhibition GO:0060134 9.71 DRD2 SLC6A3
27 central nervous system neuron development GO:0021954 9.71 LEP NPY
28 response to cocaine GO:0042220 9.71 CNR1 CRH DRD2 SLC6A3
29 neurotransmitter biosynthetic process GO:0042136 9.7 SLC6A3 SLC6A4
30 regulation of synaptic transmission, GABAergic GO:0032228 9.7 CNR1 DRD2
31 G protein-coupled receptor signaling pathway GO:0007186 9.7 CCK CNR1 CRH CRHR2 DRD2 GHRL
32 sexual reproduction GO:0019953 9.69 LEP LEPR
33 adenohypophysis development GO:0021984 9.69 DRD2 SLC6A3
34 leptin-mediated signaling pathway GO:0033210 9.68 LEP LEPR
35 monoamine transport GO:0015844 9.68 SLC6A3 SLC6A4
36 negative regulation of appetite GO:0032099 9.68 CCK LEP
37 positive regulation of growth hormone secretion GO:0060124 9.68 DRD2 GHRL
38 postsynaptic modulation of chemical synaptic transmission GO:0099170 9.67 DRD2 GHRL
39 dopamine catabolic process GO:0042420 9.67 COMT SLC6A3
40 energy reserve metabolic process GO:0006112 9.67 LEP LEPR MC4R
41 positive regulation of behavioral fear response GO:2000987 9.65 CCK CRH
42 regulation of feeding behavior GO:0060259 9.65 CNR1 LEPR MC4R
43 regulation of bone remodeling GO:0046850 9.64 LEP LEPR
44 negative regulation of glucagon secretion GO:0070093 9.63 CRH LEP
45 positive regulation of corticotropin secretion GO:0051461 9.63 CRH GHRL
46 response to ethanol GO:0045471 9.63 ADIPOQ CNR1 CRH DRD2 LEP SLC6A3
47 positive regulation of cortisol secretion GO:0051464 9.62 CRH GHRL
48 regulation of appetite GO:0032098 9.62 HTR2C POMC
49 regulation of metabolic process GO:0019222 9.61 LEP MC4R
50 positive regulation of appetite GO:0032100 9.61 GHRL NPY

Molecular functions related to Eating Disorder according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.88 CNR1 CRHR2 DRD2 HTR2C MC4R NPY
2 signaling receptor binding GO:0005102 9.7 ADIPOQ CRH DRD2 LEP NPY POMC
3 drug binding GO:0008144 9.62 CNR1 DRD2 HTR2C SLC6A3
4 G protein-coupled receptor binding GO:0001664 9.56 GHRL NPY POMC PYY
5 peptide hormone binding GO:0017046 9.54 CRHR2 LEPR MC4R
6 neurotransmitter:sodium symporter activity GO:0005328 9.51 SLC6A3 SLC6A4
7 dopamine binding GO:0035240 9.49 DRD2 SLC6A3
8 peptide hormone receptor binding GO:0051428 9.48 CCK LEP
9 serotonin binding GO:0051378 9.46 HTR2C SLC6A4
10 monoamine transmembrane transporter activity GO:0008504 9.43 SLC6A3 SLC6A4
11 neuropeptide hormone activity GO:0005184 9.26 CCK CRH NPY PYY
12 hormone activity GO:0005179 9.23 ADIPOQ CCK CRH GHRL LEP NPY

Sources for Eating Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....